Servicio de Oncología, Instituto de Oncología de la Vall d'Hebron, Barcelona, Spain.
Clin Transl Oncol. 2012 Mar;14(3):169-76. doi: 10.1007/s12094-012-0780-8.
Prostate cancer (PCa) is the most common cancer in the male population in Western countries, second to skin cancer. Hormonal therapy allows long-lasting and effective control of cancer-related symptoms in advanced stages; however, in almost all patients with metastatic PCa the disease will progress when it becomes castration-resistant (CRPC). Chemotherapy with docetaxel was a turning point in CRPC, as, for the first time, it resulted in an increased survival time in comparison with mitoxantrone and prednisone. Combination therapy with docetaxel and prednisone is the first-line treatment of choice. Once the cancer has progressed, there is no clear alternative, although some new agents have shown promise in the treatment of this type of cancer. This review will provide an overview of the current status of CRPC, including clinical status, prognosis, firstline treatment and new second-line treatment options.
前列腺癌（PCa）是西方国家男性人群中最常见的癌症，仅次于皮肤癌。激素治疗可在晚期有效控制与癌症相关的症状，但几乎所有转移性 PCa 患者在发生去势抵抗性（CRPC）时疾病都会进展。多西他赛化疗是 CRPC 的一个转折点，因为它首次使患者的生存时间比米托蒽醌和泼尼松延长。多西他赛和泼尼松联合治疗是首选的一线治疗。一旦癌症进展，就没有明确的替代方案，尽管一些新药物在治疗这种类型的癌症方面显示出了希望。这篇综述将概述 CRPC 的现状，包括临床状况、预后、一线治疗和新的二线治疗选择。
